Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03661320




Registration number
NCT03661320
Ethics application status
Date submitted
5/09/2018
Date registered
7/09/2018
Date last updated
30/01/2024

Titles & IDs
Public title
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
Scientific title
A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy Alone Versus Neoadjuvant Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post- Surgery Therapy With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle- Invasive Bladder Cancer
Secondary ID [1] 0 0
2017-004692-31
Secondary ID [2] 0 0
CA017-078
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Urinary Bladder Neoplasms 0 0
Muscle-Invasive Bladder Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Bladder - transitional cell cancer

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - Nivolumab
Treatment: Drugs - Gemcitabine
Treatment: Drugs - Cisplatin

Active comparator: Arm A: Gemcitabine/Cisplatin (GC) Chemotherapy -

Experimental: Arm B: Nivolumab + GC Chemotherapy -


Treatment: Other: Nivolumab
Specified dose on specified days

Treatment: Drugs: Gemcitabine
Specified dose on specified days

Treatment: Drugs: Cisplatin
Specified dose on specified days
Intervention code [1] 0 0
Treatment: Other
Intervention code [2] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Pathological Complete Response (pCR) rate, in all randomized participants
Timepoint [1] 0 0
Approximately 43 months
Primary outcome [2] 0 0
Event-Free Survival (EFS), in all randomized participants
Timepoint [2] 0 0
Approximately 51 months
Secondary outcome [1] 0 0
Overall Survival (OS) in all randomized participants
Timepoint [1] 0 0
Approximately 60 months
Secondary outcome [2] 0 0
Incidence of Adverse Events (AE) in participants who received at least one treatment dose
Timepoint [2] 0 0
Approximately 60 months
Secondary outcome [3] 0 0
Incidence of Serious Adverse Events (SAE) in participants who received at least one treatment dose
Timepoint [3] 0 0
Approximately 60 months
Secondary outcome [4] 0 0
Incidence of deaths in participants who received at least one treatment dose
Timepoint [4] 0 0
Approximately 60 months
Secondary outcome [5] 0 0
Incidence of laboratory abnormalities in participants who received at least one treatment dose
Timepoint [5] 0 0
Approximately 60 months
Secondary outcome [6] 0 0
pCR rate, descriptively in all concurrently randomized participants
Timepoint [6] 0 0
Approximately 43 months
Secondary outcome [7] 0 0
EFS, descriptively in all concurrently randomized participants
Timepoint [7] 0 0
Approximately 51 months
Secondary outcome [8] 0 0
OS, descriptively in all concurrently randomized participants
Timepoint [8] 0 0
Approximately 60 months

Eligibility
Key inclusion criteria
* Participant must be deemed eligible for Radial Cystectomy (RC) by his/her oncologist and/or urologist, and must agree to undergo Radial Cystectomy (RC) after completion of neoadjuvant therapy.
* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Clinical evidence of positive lymph node(s) (LN) (= 10 mm in short axis) or metastatic bladder cancer
* Prior systemic therapy, radiation therapy, or surgery for bladder cancer other than trans urethral resection of bladder tumor (TURBT) or biopsies is also not permitted

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
6/11/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
30/12/2027
Actual
Sample size
Target
Accrual to date
Final
861
Recruitment in Australia
Recruitment state(s)
ACT,NSW,SA,VIC,WA
Recruitment hospital [1] 0 0
Local Institution - 0131 - Garran
Recruitment hospital [2] 0 0
Local Institution - 0130 - Kingswood
Recruitment hospital [3] 0 0
Local Institution - 0157 - Macquarie University
Recruitment hospital [4] 0 0
Local Institution - 0043 - St Leonards
Recruitment hospital [5] 0 0
Local Institution - 0143 - North Adelaide
Recruitment hospital [6] 0 0
Local Institution - 0037 - Heidelberg
Recruitment hospital [7] 0 0
Local Institution - 0038 - Murdoch
Recruitment postcode(s) [1] 0 0
2605 - Garran
Recruitment postcode(s) [2] 0 0
2747 - Kingswood
Recruitment postcode(s) [3] 0 0
2109 - Macquarie University
Recruitment postcode(s) [4] 0 0
2065 - St Leonards
Recruitment postcode(s) [5] 0 0
5006 - North Adelaide
Recruitment postcode(s) [6] 0 0
3084 - Heidelberg
Recruitment postcode(s) [7] 0 0
6150 - Murdoch
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Maryland
Country [8] 0 0
United States of America
State/province [8] 0 0
Massachusetts
Country [9] 0 0
United States of America
State/province [9] 0 0
Minnesota
Country [10] 0 0
United States of America
State/province [10] 0 0
Nebraska
Country [11] 0 0
United States of America
State/province [11] 0 0
Nevada
Country [12] 0 0
United States of America
State/province [12] 0 0
New York
Country [13] 0 0
United States of America
State/province [13] 0 0
Ohio
Country [14] 0 0
United States of America
State/province [14] 0 0
Oregon
Country [15] 0 0
United States of America
State/province [15] 0 0
South Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
Tennessee
Country [17] 0 0
United States of America
State/province [17] 0 0
Texas
Country [18] 0 0
United States of America
State/province [18] 0 0
Virginia
Country [19] 0 0
Argentina
State/province [19] 0 0
Buenos Aires
Country [20] 0 0
Argentina
State/province [20] 0 0
Distrito Federal
Country [21] 0 0
Austria
State/province [21] 0 0
Klagenfurt Am Woerthersee
Country [22] 0 0
Austria
State/province [22] 0 0
Krems
Country [23] 0 0
Austria
State/province [23] 0 0
Linz
Country [24] 0 0
Austria
State/province [24] 0 0
Wien
Country [25] 0 0
Belgium
State/province [25] 0 0
Bruxelles
Country [26] 0 0
Belgium
State/province [26] 0 0
Gent
Country [27] 0 0
Belgium
State/province [27] 0 0
Wilrijk
Country [28] 0 0
Brazil
State/province [28] 0 0
Ceara
Country [29] 0 0
Brazil
State/province [29] 0 0
Minas Gerais
Country [30] 0 0
Brazil
State/province [30] 0 0
RIO Grande DO SUL
Country [31] 0 0
Brazil
State/province [31] 0 0
Sao Paulo
Country [32] 0 0
Brazil
State/province [32] 0 0
Rio De Janeiro
Country [33] 0 0
Canada
State/province [33] 0 0
British Columbia
Country [34] 0 0
Canada
State/province [34] 0 0
Ontario
Country [35] 0 0
Canada
State/province [35] 0 0
Quebec
Country [36] 0 0
Chile
State/province [36] 0 0
Metropolitana
Country [37] 0 0
Colombia
State/province [37] 0 0
Bogota
Country [38] 0 0
Colombia
State/province [38] 0 0
Bucaramanga
Country [39] 0 0
Colombia
State/province [39] 0 0
Monteria
Country [40] 0 0
Finland
State/province [40] 0 0
Helsinki
Country [41] 0 0
Finland
State/province [41] 0 0
Tampere
Country [42] 0 0
Finland
State/province [42] 0 0
Turku
Country [43] 0 0
France
State/province [43] 0 0
Cedex
Country [44] 0 0
France
State/province [44] 0 0
Val-de-Marne
Country [45] 0 0
France
State/province [45] 0 0
Amiens
Country [46] 0 0
France
State/province [46] 0 0
Angers
Country [47] 0 0
France
State/province [47] 0 0
Besancon
Country [48] 0 0
France
State/province [48] 0 0
Bordeaux
Country [49] 0 0
France
State/province [49] 0 0
Clermont-ferrand
Country [50] 0 0
France
State/province [50] 0 0
La Tronche
Country [51] 0 0
France
State/province [51] 0 0
Marseille
Country [52] 0 0
France
State/province [52] 0 0
Montpellier Cedex 5
Country [53] 0 0
France
State/province [53] 0 0
Nice
Country [54] 0 0
France
State/province [54] 0 0
Paris
Country [55] 0 0
France
State/province [55] 0 0
Pierre Benite Cedax
Country [56] 0 0
France
State/province [56] 0 0
Saint Herblain Cedex
Country [57] 0 0
France
State/province [57] 0 0
Strasbourg Cedex
Country [58] 0 0
France
State/province [58] 0 0
TOULOUSE Cedex 9
Country [59] 0 0
Germany
State/province [59] 0 0
Rheinland-Pfalz
Country [60] 0 0
Germany
State/province [60] 0 0
Aachen
Country [61] 0 0
Germany
State/province [61] 0 0
Erfurt
Country [62] 0 0
Germany
State/province [62] 0 0
Essen
Country [63] 0 0
Germany
State/province [63] 0 0
Frankfurt Main
Country [64] 0 0
Germany
State/province [64] 0 0
Goettingen
Country [65] 0 0
Germany
State/province [65] 0 0
Herne
Country [66] 0 0
Germany
State/province [66] 0 0
Jena
Country [67] 0 0
Germany
State/province [67] 0 0
Luebeck
Country [68] 0 0
Germany
State/province [68] 0 0
Magdeburg
Country [69] 0 0
Germany
State/province [69] 0 0
Muenchen
Country [70] 0 0
Germany
State/province [70] 0 0
Nuernberg
Country [71] 0 0
Germany
State/province [71] 0 0
Trier
Country [72] 0 0
Greece
State/province [72] 0 0
Attikí
Country [73] 0 0
Greece
State/province [73] 0 0
Thessalía
Country [74] 0 0
Greece
State/province [74] 0 0
Chaidari
Country [75] 0 0
Israel
State/province [75] 0 0
Tel-Aviv
Country [76] 0 0
Israel
State/province [76] 0 0
Beer Sheva
Country [77] 0 0
Israel
State/province [77] 0 0
Haifa
Country [78] 0 0
Israel
State/province [78] 0 0
Ramat Gan
Country [79] 0 0
Italy
State/province [79] 0 0
Bari
Country [80] 0 0
Italy
State/province [80] 0 0
Forlì
Country [81] 0 0
Italy
State/province [81] 0 0
Milano
Country [82] 0 0
Italy
State/province [82] 0 0
Modena
Country [83] 0 0
Italy
State/province [83] 0 0
Padova
Country [84] 0 0
Italy
State/province [84] 0 0
Pisa
Country [85] 0 0
Italy
State/province [85] 0 0
Roma
Country [86] 0 0
Japan
State/province [86] 0 0
Aichi
Country [87] 0 0
Japan
State/province [87] 0 0
Hokkaido
Country [88] 0 0
Japan
State/province [88] 0 0
Ibaraki
Country [89] 0 0
Japan
State/province [89] 0 0
Kagawa
Country [90] 0 0
Japan
State/province [90] 0 0
Kanagawa
Country [91] 0 0
Japan
State/province [91] 0 0
Niigata
Country [92] 0 0
Japan
State/province [92] 0 0
Osaka
Country [93] 0 0
Japan
State/province [93] 0 0
Saitama
Country [94] 0 0
Japan
State/province [94] 0 0
Shizuoka
Country [95] 0 0
Japan
State/province [95] 0 0
Tokyo
Country [96] 0 0
Japan
State/province [96] 0 0
Fukuoka
Country [97] 0 0
Japan
State/province [97] 0 0
Kyoto
Country [98] 0 0
Korea, Republic of
State/province [98] 0 0
Gyeonggi-do
Country [99] 0 0
Korea, Republic of
State/province [99] 0 0
Kyonggi-do
Country [100] 0 0
Korea, Republic of
State/province [100] 0 0
Busan
Country [101] 0 0
Korea, Republic of
State/province [101] 0 0
Daegu
Country [102] 0 0
Korea, Republic of
State/province [102] 0 0
Gyeongsangnam-do
Country [103] 0 0
Korea, Republic of
State/province [103] 0 0
Seongnam-si,
Country [104] 0 0
Korea, Republic of
State/province [104] 0 0
Seoul
Country [105] 0 0
Mexico
State/province [105] 0 0
BAJA Californa SUR
Country [106] 0 0
Mexico
State/province [106] 0 0
Jalisco
Country [107] 0 0
Mexico
State/province [107] 0 0
Nuevo LEON
Country [108] 0 0
Mexico
State/province [108] 0 0
Colima
Country [109] 0 0
Netherlands
State/province [109] 0 0
Amsterdam
Country [110] 0 0
Netherlands
State/province [110] 0 0
Groningen
Country [111] 0 0
Netherlands
State/province [111] 0 0
Sittard-Geleen
Country [112] 0 0
New Zealand
State/province [112] 0 0
Auckland
Country [113] 0 0
New Zealand
State/province [113] 0 0
Christchurch
Country [114] 0 0
Norway
State/province [114] 0 0
Gralum
Country [115] 0 0
Norway
State/province [115] 0 0
Lorenskog
Country [116] 0 0
Norway
State/province [116] 0 0
Oslo
Country [117] 0 0
Portugal
State/province [117] 0 0
Lisboa
Country [118] 0 0
Portugal
State/province [118] 0 0
Porto
Country [119] 0 0
Romania
State/province [119] 0 0
Cluj-Napoca
Country [120] 0 0
Romania
State/province [120] 0 0
Craiova
Country [121] 0 0
Romania
State/province [121] 0 0
Sector 2
Country [122] 0 0
Russian Federation
State/province [122] 0 0
Saint-Petersburg
Country [123] 0 0
Russian Federation
State/province [123] 0 0
St Petersburg
Country [124] 0 0
Singapore
State/province [124] 0 0
Singapore
Country [125] 0 0
Spain
State/province [125] 0 0
Lugo
Country [126] 0 0
Spain
State/province [126] 0 0
Madrid
Country [127] 0 0
Spain
State/province [127] 0 0
Malaga
Country [128] 0 0
Spain
State/province [128] 0 0
Sevilla
Country [129] 0 0
Taiwan
State/province [129] 0 0
Kaohsiung
Country [130] 0 0
Taiwan
State/province [130] 0 0
Taichung
Country [131] 0 0
Taiwan
State/province [131] 0 0
Taipei City
Country [132] 0 0
Taiwan
State/province [132] 0 0
Taipei
Country [133] 0 0
United Kingdom
State/province [133] 0 0
Essex
Country [134] 0 0
United Kingdom
State/province [134] 0 0
Yorkshire
Country [135] 0 0
United Kingdom
State/province [135] 0 0
Glasgow
Country [136] 0 0
United Kingdom
State/province [136] 0 0
Lancaster
Country [137] 0 0
United Kingdom
State/province [137] 0 0
London
Country [138] 0 0
United Kingdom
State/province [138] 0 0
Oxford

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Bristol-Myers Squibb
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Ono Pharmaceutical Co. Ltd
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to compare nivolumab plus neoadjuvant gemcitabine/cisplatin (GC) chemotherapy, followed by post-surgery continuation of immuno-oncology (IO) therapy, with neoadjuvant GC chemotherapy alone in adult participants with previously untreated muscle-invasive bladder cancer (MIBC).
Trial website
https://clinicaltrials.gov/study/NCT03661320
Trial related presentations / publications
Sonpavde G, Necchi A, Gupta S, Steinberg GD, Gschwend JE, Van Der Heijden MS, Garzon N, Ibrahim M, Raybold B, Liaw D, Rutstein M, Galsky MD. ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer. Future Oncol. 2020 Jan;16(2):4359-4368. doi: 10.2217/fon-2019-0611. Epub 2019 Dec 11.
Public notes

Contacts
Principal investigator
Name 0 0
Bristol-Myers Squibb
Address 0 0
Bristol-Myers Squibb
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT03661320